Key result
Elevated FGF23 in CKD is linked to increased risk of LVH and adverse cardiovascular outcomes.
Why the study?
Fibroblast growth factor 23 (FGF23) rises early in chronic kidney disease (CKD) and is linked to cardiac remodeling, but consistency across studies is unclear.
Meta-Analysis
This rapid review and exploratory quantitative synthesis indicates that elevated FGF23 in chronic kidney disease is directionally associated with adverse cardiac remodeling and higher risk of heart failure or cardiovascular mortality, though current evidence certainty remains very low.
Answers are grounded in this paper and cite their sources.
May support FGF23 as a biomarker for HF/CV risk in CKD; leaves open causality and need for interventional trials.
Left ventricular hypertrophy (LVH), elevated left ventricular mass index (LVMI), diastolic dysfunction, heart failure, and cardiovascular mortality are common in chronic kidney disease (CKD). Fibroblast growth factor 23 (FGF23) rises early in CKD and is linked to cardiac remodeling, but consistency across studies is unclear. We conducted a rapid review of FGF23 and cardiac outcomes in CKD, incorporating a reanalyzed unpublished single-center cohort, and pooled effect estimates where at least 2 studies reported comparable metrics. A structured web-based search (August 2026) identified 11 candidate studies on FGF23 and cardiac outcomes in CKD; 9 met eligibility, including 1 unpublished investigator-held cohort (n = 80) reanalyzed for this review. Pooling (inverse variance) was performed only where at least 2 studies reported comparable metrics; all pooled estimates are exploratory, below the prespecified 3-study minimum. For FGF23 and LVH, using a derived LVH variable from the present cohort, a pooled log-FGF23 odds ratio (OR) across 2 adult-CKD studies (n = 242) was 1.33 (95% confidence interval [CI] 0.92-1.93), I2 = 78%; a pediatric study (OR 2.53, n = 587) was consistent in direction but unpooled. For LVMI, correlations were not pooled; a Chronic Renal Insufficiency Cohort cohort showed higher LVMI only in the top quartile. For heart failure/cardiovascular mortality, a pooled hazard ratio across 2 studies (n = 374) was 2.37 (95% CI 1.47-3.84), I2 = 0%, with LVMI mediating only 7-22% in Chronic Renal Insufficiency Cohort. FGF23 was not significantly associated with diastolic dysfunction after adjustment (OR 1.51/standard deviation, 95% CI 0.92-2.47). The available evidence, though sparse and heterogeneous, is directionally consistent with a positive FGF23-cardiac remodeling association in CKD. Certainty is very low throughout; a full multi-database search is needed before a definitive conclusion.
No takes yet. Share an insight, caveat, or question.
Chakola et al. (2026) conducted a meta-analysis in Chronic kidney disease. Fibroblast growth factor 23 (FGF23) vs. Lower FGF23 levels was evaluated on Left ventricular hypertrophy (LVH) (OR 1.33, 95% CI 0.92-1.93). Elevated FGF23 in CKD was associated with heart failure/CV mortality and directionally linked to LVH.
Synapse has enriched 10 related papers. Consider them for comparative context: